FOX Translator

Detach

No data currently available.

No data currently available.

Commodity

Even if you don't think you do, you already know plenty about commodities. Want us to prove it? No problem.

What makes oil produced in Saudi Arabia different from oil exported from Nigeria? It's the same thing that makes the corn you ate at last summer¿s barbecue different from the corn used to produce ethanol. Stumped? Well, don't feel bad, it's a trick question. The answer? Absolutely nothing. Corn is corn no matter where it comes from -- just as wheat is wheat and natural gas is -- right! -- natural gas. (Though the quality may differ, the make-up is uniform.)

So, in less elaborate terms, corn and oil (and all other commodities) are homogenous goods that can be processed, resold and more often than not, used as an input to the production of other goods or services. These goods are traded on a commodity exchange, thus setting the price-per-barrel (or other metric unit) used to value them.

Now pay attention, here's a question that indeed does have an answer: What is the difference between a commodity and a stock? While a stock can tank and become worthless, a commodity cannot have its value be wiped to zero. One other difference: Most commodities are traded in futures, meaning traders buy and sell where they think the price of a product will be at a certain point in the future. Stocks trade based on the value of the underlying company at that point in time.

Home / Markets / Industries / Health Care

BioCurex Retains AGORACOM to Provide Investor Relations, Social Network and Google Search Engine Program

 
Comtex
 

VANCOUVER, BRITISH COLUMBIA, Jul 24, 2008 (MARKET WIRE via COMTEX) ----BioCurex (OTCBB: BOCX) is pleased to announce it has retained the services of AGORACOM Investor Relations ("AGORACOM") (http://www.agoracom.com) to provide online investor relations services, a Web 2.0 social network for current shareholders and Tier-1 awareness through the world's biggest websites for the purpose of attracting new shareholders.

ONLINE INVESTOR RELATIONS MAXIMIZES SPEED, TRANSPARENCY AND ACCESS TO COMPANY

In response to overwhelming data representing the online research and communications habits of small-cap investors, BioCurex has turned the primary focus of its investor relations to the web via the AGORACOM system to facilitate faster, better and more accessible communications with both current and prospective shareholders around the world.

Effective immediately, a customized and monitored BioCurex IR Hub (http://www.agoracom.com/IR/Biocurex) will allow both the Company and AGORACOM to communicate with all investors simultaneously, anytime and in near real-time. Our new IR HUB will also provide management with an ability to extend communications beyond text via audio messages, video presentations, webcasts and podcasts. In addition to traditional e-mail, investors will also have the ability to receive all communications via RSS feed.

LAUNCH OF BIOCUREX COMMUNITY

The BioCurex IR HUB propels the Company into the forefront of Web 2.0 community building by providing investors with two very important functions. First, a monitored discussion forum for the purposes of constructive and high-quality discussion amongst investors that is free of spam, profanity and misinformation. Second, a social network that provides investors with the ability to create extensive profiles that include photos, bios, video messages to fellow investors, a rating system and other important items to create a closer bond between our shareholders.

TIER-1 EXPOSURE AND AWARENESS

AGORACOM will be launching a search engine IR Program via Google and Yahoo that specifically targets prospective small-cap investors across North America. These small-cap search engine programs are exclusive to AGORACOM, with creation and management coming from Yahoo and Google personnel directly.

In addition, as an exclusive provider of "Small-Cap Centres - Powered by AGORACOM" to every Blackberry device on the planet, Yahoo Finance Canada and AOL Finance Canada, reaching a total audience of 1.4 million small-cap investors, AGORACOM will provide Tier-1 financial coverage of all newsworthy BioCurex press releases for the purposes of attracting new and prospective shareholders.

BioCurex Chairman Gerry Wittenberg stated, "I believe the time has now come to significantly increase our communications with both existing shareholders and the massive online small-cap community of investors that are searching for their next great investment. I strongly encourage our shareholders to begin taking advantage of our new online IR system, which demonstrates we are a fully accessible organization with a great story to tell."

For all future BioCurex investor relations needs, investors are asked to visit our IR Hub at http://www.agoracom.com/IR/Biocurex where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors.

About AGORACOM

AGORACOM Investor Relations (http://www.AgoracomIR.com) is North America's largest online investor relations firm for small-cap companies. We have partnered with the world's biggest internet companies, including Yahoo, AOL, Google and Blackberry to market our clients to a massive audience of new small-cap investors. We have served over 200 companies since 1997.

AGORACOM Investor Relations has displaced the telephone and e-mail as primary IR communications devices. Our IR HUB delivers two-way investor relations in near real-time that is 24/7/365 accessible to shareholders around the world and goes far beyond text by offering both audio and video communications.

AGORACOM (http://www.Agoracom.com) is North America's only small-cap community built to serve the needs of serious small-cap and micro-cap investors. No rumours, profanity, stock bashing or hyping. Our traffic ranking is above the top 1% of all websites around the world.

About BioCurex

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for further information on these agreements see: http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt).

The cancer marker RECAF(TM) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

To read more about the Company, please visit the News section in our web site (http://www.biocurex.com).

Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

 Contacts: BioCurex, Inc. Corporate Inquiries:
   Ricardo Moro (604) 207-9150 Investor Relations AGORACOM Investor Relations Email: BOCX@agoracom.com Website: http://www.agoracom.com/IR/Biocurex
   

SOURCE: BioCurex, Inc.

mailto:BOCX@agoracom.com http://www.agoracom.com/IR/Biocurex 
Copyright
   2008 Market Wire, All rights reserved.
 

Market Snapshot

Symbol Last Price Netchange Volume
-- -- -- --
-- -- -- --
-- -- -- --
-- -- -- --
-- -- -- --